Biochemistry analyzers market seen reaching $6.69 billion by 2030

The biochemistry analyzers market is projected to grow from $4.82 billion in 2025 to $6.69 billion by 2030 as chronic disease testing, lab automation and point-of-care diagnostics expand. North America led in 2025, while Asia-Pacific is forecast to be the fastest-growing region.

Why it matters: - Biochemistry analyzers are central to clinical diagnostics because they measure biochemical substances in biological samples and help doctors detect, monitor and manage disease. - Market growth points to rising demand for testing tied to chronic illness, preventive care and faster diagnostic workflows.

What happened: - The Business Research Company published a 2026 report on the global biochemistry analyzers market on July 28, 2026. - The market is estimated at $4.82 billion in 2025 and is projected to reach $5.16 billion in 2026. - The market is forecast to rise to $6.69 billion by 2030. - The report places North America as the largest regional market in 2025. - The report identifies Asia-Pacific as the fastest-growing region over the forecast period. - A free sample report is available here. - The full report is available here.

The details: - The market expanded in recent years on the back of more clinical testing services, broader hospital diagnostics, more chronic disease cases, laboratory automation and steady reagent availability. - Growth from 2025 to 2026 implies a 7.0% compound annual growth rate. - Growth from 2026 to 2030 implies a 6.7% compound annual growth rate. - Major growth drivers ahead include point-of-care testing, AI-enabled analyzers, consolidation in laboratory operations, an aging population and demand for preventive diagnostics. - Key trends include high-throughput diagnostic techniques, more automation in clinical laboratories, expansion of point-of-care biochemistry testing, multi-parameter testing and a focus on chronic disease diagnostics. - Biochemistry analyzers quantify biochemical components in blood, urine, serum, plasma and cerebrospinal fluid. - These instruments support evaluation of chemical reactions and metabolic functions, organ-health monitoring and disease identification. - Chronic disease prevalence is a major demand driver because clinicians use biochemistry analyzers to measure biomarkers for diagnosis, monitoring and treatment response. - Allergy UK reported in April 2024 that more than 21 million people in the United Kingdom suffer from allergies, the most commonly reported chronic condition in 2022. - Projections cited in the report suggest half of Europe’s population will experience at least one allergy by 2026. - The regional analysis covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

Between the lines: - The report’s forecast suggests biochemistry analyzers are becoming more tied to routine, higher-volume care rather than only specialized lab work. - The strongest demand signals cluster around automation, faster turnaround and chronic disease management, which favors systems that can process more tests with less manual handling. - North America’s lead reflects mature healthcare spending and diagnostics adoption, while Asia-Pacific’s growth outlook suggests room for new lab capacity and testing access to expand.

What's next: - The market is expected to keep rising through 2030 as hospitals and labs add more automated and point-of-care testing capacity. - Product development is likely to center on AI integration, higher throughput and multi-parameter testing. - The report says its 2026 editions include market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel forecasting dashboards, market hotspot infographics, and updated graphics and tables.